- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturing capabilities with new facilities in Ireland LONDON and NEW YORK, Aug.

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin , M.D. as chief medical officer (CMO). A clinical immunologist by training, Dr.

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting   • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial   • Based on encouraging safety and efficacy profile, MeiraGTx and Janssen expect to progress AAV-RPGR into

LONDON and NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that its 2020 Annual General Meeting of Shareholders scheduled for Tuesday, June 2, 2020 at 10:00 a.m.

LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress.

LONDON and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Virtual Bank of America Securities

LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 2019 and provided an update on recent progress.

PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR AAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated,

LONDON and NEW YORK , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health